Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 2,687 Cr.
- Current Price ₹ 470
- High / Low ₹ 590 / 443
- Stock P/E 40.5
- Book Value ₹ 67.9
- Dividend Yield 0.00 %
- ROCE 23.8 %
- ROE 27.3 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
356 | 373 | 411 | 801 | 926 | |
315 | 322 | 356 | 704 | 813 | |
Operating Profit | 41 | 51 | 54 | 96 | 114 |
OPM % | 11% | 14% | 13% | 12% | 12% |
0 | 1 | 1 | 3 | 9 | |
Interest | 6 | 5 | 4 | 6 | 20 |
Depreciation | 11 | 10 | 6 | 8 | 11 |
Profit before tax | 25 | 38 | 46 | 86 | 92 |
Tax % | 20% | 26% | 26% | 25% | 26% |
20 | 28 | 34 | 64 | 68 | |
EPS in Rs | 165.67 | 232.42 | 287.50 | 532.92 | 14.16 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 35% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 33% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 30% |
Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 48 | 48 |
Reserves | 70 | 98 | 133 | 197 | 229 | 341 |
Preference Capital | 0 | 0 | 0 | 0 | 47 | |
72 | 54 | 46 | 199 | 190 | 520 | |
68 | 81 | 179 | 167 | 238 | 265 | |
Total Liabilities | 223 | 245 | 370 | 575 | 704 | 1,173 |
78 | 73 | 79 | 183 | 183 | 352 | |
CWIP | 0 | 0 | 7 | 0 | 22 | 173 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
144 | 172 | 283 | 392 | 500 | 648 | |
Total Assets | 223 | 245 | 370 | 575 | 704 | 1,173 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
19 | 31 | 42 | 59 | 67 | |
-9 | -6 | -20 | -188 | -91 | |
-9 | -23 | -19 | 125 | 27 | |
Net Cash Flow | 1 | 1 | 3 | -5 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Debtor Days | 93 | 85 | 123 | 97 | 104 |
Inventory Days | 50 | 84 | 107 | 76 | 62 |
Days Payable | 80 | 92 | 132 | 86 | 84 |
Cash Conversion Cycle | 64 | 77 | 99 | 87 | 83 |
Working Capital Days | 77 | 86 | 73 | 97 | 98 |
ROCE % | 26% | 28% | 31% | 24% |
Documents
Announcements
- Compliance Certificate For The Financial Year Ended March 31, 2024 Pursuant To Regulation Under 40((9&10) The SEBI (LODR), Regulations 2015. 18 Apr
- Compliance Certificate For The Financial Year Ended March 31, 2024 Pursuant To Regulation 7(3) Of SEBI (LODR), Regulations 2015, As Amended From Time To Time ('SEBI Listing Regulations') 15 Apr
- Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 (The 'Listing Regulations') 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Certificate Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, for the quarter ended March 31, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 Apr - Of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR), Regulations 2015.
Concalls
-
Feb 2024Transcript PPT
About the company[1] Sharon is engaged in the business of manufacturing intermediates, API, and formulations. It offers contract manufacturing services for pharmaceutical products and made sales worth 192 Crs.